TY - JOUR T1 - Should gatifloxacin be included in the model list of essential medicines? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02329-2017 VL - 51 IS - 2 SP - 1702329 AU - Chen-Yuan Chiang AU - Arnaud Trébucq AU - Alberto Piubello AU - Hans L. Rieder AU - Armand Van Deun Y1 - 2018/02/01 UR - http://erj.ersjournals.com/content/51/2/1702329.abstract N2 - We read with great interest the paper by Falzon et al. [1], which reported that gatifloxacin and moxifloxacin have been recommended by the World Health Organization (WHO) for both longer and shortened regimens in the treatment of rifampicin-resistant (RR) and multidrug-resistant (MDR) tuberculosis (TB). Gatifloxacin and moxifloxacin belong to the latest generation of fluoroquinolones that have comparable early bactericidal and sterilising activity in the treatment of TB. Gatifloxacin has been used in the treatment of bacterial infections and MDR-TB [2]. Gatifloxacin was also used in a clinical trial (OFLOTUB) comparing a 4-month gatifloxacin-based regimen with the standard 6-month regimen for the treatment of rifampicin-susceptible pulmonary TB [3]. The gatifloxacin-based shortened treatment was highly effective, achieving >84% treatment success among MDR-TB patients in Bangladesh, Cameroon and Niger [2].Moxifloxacin may not be a valid alternative to gatifloxacin in the treatment of multidrug-resistant tuberculosis http://ow.ly/uLby30hBItG ER -